These observations point out, that current NGS and bioinformatics methods cannot fully replace other laboratory tests for mutation screening in AML, as FLT3-ITDs represent therapeutic targets already in the first line of treatment that must not be overlooked37,38. The gene discussed is FLT3; the disease is acute myeloid leukemia.